약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 6.

Table. 6.

Causal inference approach of the association of statin use with cirrhosis and hepatocellular carcinoma according to underlying liver disease

Outcome Underlying liver disease (N) IPW analysis Superlearning TMLE


Marginal OR 95% CI Marginal OR 95% CI
Cirrhosis Hepatitis B virus (2,392 ) 0.39** 0.16-0.59 0.37** 0.19-0.55
Hepatitis C virus (892 ) - - 0.95 0.05-1.86
NAFLD (6,894) 0.68** 0.50-0.87 0.64** 0.46-0.81
Other chronic hepatitis (12,410 ) 0.56** 0.48-0.63 0.51** 0.43-0.58
Alcoholic liver disease (7,079) 0.57** 0.44-0.70 0.53** 0.40-0.65
Toxic liver disease (2,899) 0.95 0.51-1.39 0.76 0.35-1.17
Hepatocellular carcinoma Hepatitis B virus (2,392 ) 0.51** 0.21-0.82 0.53** 0.26-0.80
Hepatitis C virus (892 ) - - 0.22** 0.02-0.46
NAFLD (6,894) 0.64** 0.40-0.88 0.63** 0.39-0.88
Other chronic hepatitis (12,410 ) 0.52** 0.44-0.61 0.52** 0.43-0.61
Alcoholic liver disease (7,079) 0.73* 0.50-0.96 0.67** 0.44-0.89
Toxic liver disease (2,899) 1.04 0.38-1.70 0.98 0.31-1.65

Adjusted for dyslipidemia, cardiovascular disease, hypertension, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

* p<0.05, ** p<0.01

Yakhak Hoeji 2024;68:44-55 https://doi.org/10.17480/psk.2024.68.1.44
© 2024 Yakhak Hoeji